ANNX
Annexon, Inc.Healthcare · $657M market cap
Verdict
We can't put a fair value on ANNX right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow ANNX
Track it on your watchlist and see the full analysis. Free.
Create a free accountSuperinvestors
None of the investors we track holds ANNX right now. In Q2 2026, 1 sold out. Who we track
Moves in Q2 2026
Sold out: Polen Capital Management
About Annexon, Inc.
Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works